The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
Abstract
Background Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition. Methods 618 patients with moderate to severe psoriasis received double-blind treatment with placebo or 50 mg twice-weekly etanercept. The primary efficacy endpoint was a 75% or greater improvement from baseline in psoriasis area and severity index score (PASI 75) at week 12. Secondary and other endpoints included the functional assessment of chronic illness therapy fatigue (FACIT-F) scale, the Hamilton rating scale for depression (Ham-D), the Beck depression inventory (BDI), and adverse events. Efficacy analyses were based on the allocated treatment. Analyses and summaries of safety data were based on the actual treatment received. This study is registered with with the identifier NCT00111449. Findings 47% (147 of 311) of patients achieved PASI 75 at week 12, compared with 5% (15 of 306) of those receiving placebo (p Interpretation Etanercept treatment might relieve fatigue and symptoms of depression associated with this chronic disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At Week 12, 43% and 55% of patients in the etanercept treatment group were categorized as responders as assessed by the HRSD and BDI, respectively, compared to only 32% and 39% of patients in the placebo group.”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Tyring et al., 2006
In the citing paper
“whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Tyring et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Tyring et al., 2006
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [27]
In the citing paper
“Encouraging results have been obtained by blocking TNF-α in patients with psoriasis80”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [80]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citationCategorical Data Analysis Using the SAS System
(1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 1,869
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationVgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Kales, A., Tyson, K., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3950 · Cited by 974
Krueger, G. G., Koo, J. Y. M., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001) · PubMed · Cited by 969
Fatigue in cancer patients compared with fatigue in the general United States population
Cella, D., Lai, J., Chang, C., Peterman, A., & Slavin, M. (2002) · Cancer · doi:10.1002/cncr.10245 · Cited by 841
Self-citationCella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Self-citationStern, R. S., Nijsten, T., Feldman, S. R., Margolis, D. J., & Rolstad, T. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2003.09102.x · Cited by 732
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
“For example, in a large double-blind, placebo-controlled trial of the TNF-alpha antagonist, etanercept, for the treatment of psoriasis, participants who received etanercept exhibited significant improvement in depressive symptoms compared with placebotreated subjects, an effect that was independent of improvement in d…”
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Metadata
- Authors
- Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., Cella, D., & Krishnan, R.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Rutgers, The State University of New Jersey (US)
- Western University (CA)
- Saint Louis University (US)
- Amgen (United States) (US)
- Northwestern University (US)
- Duke University (US)
- Corresponding author
- Krishnan, Ranga
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 367
- Issue
- 9504
- Pages
- 29-35
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2168911501
- Cited by
- 1,069
- References
- 40
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 34 · 2023: 36 · 2022: 48 · 2021: 44 · 2020: 70 · 2019: 55 · 2018: 69 · 2017: 51 · 2016: 68 · 2015: 71 · 2014: 65 · 2013: 72 · 2012: 69
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- etanercept, psoriasis, fatigue, depression, TNF-alpha inhibitors, PASI 75, FACIT-Fatigue, Hamilton Depression Rating Scale, Beck Depression Inventory, joint pain
- MeSH terms
- Etanercept, Anti-Inflammatory Agents, Non-Steroidal, Depression, Double-Blind Method, Fatigue, Female, Humans, Immunoglobulin G, Male, Middle Aged, Psoriasis, Severity of Illness Index, Receptors, Tumor Necrosis Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. https://app.cochat.ai/papers/10.1016/s0140-6736(05)67763-x
- The paper
- Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., Cella, D., & Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. The Lancet. https://doi.org/10.1016/s0140-6736(05)67763-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.